Madrigal Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Rezdiffra’s launch has driven rapid sales growth and market expansion, with over 42,250 patients treated and strong prescriber adoption. The company is leveraging its first-mover advantage, robust pipeline, and favorable financials to pursue long-term leadership in the growing MASH market.
-
Rezdiffra delivered $311M in Q1 2026 net sales, up 127% year-over-year, with over 42,250 active patients and a rapidly expanding MASH market. The company is investing in a robust pipeline, including new siRNA assets, and expects continued strong growth, though profitability is not anticipated in 2026.
-
Rezdiffra is experiencing strong growth, with 2025 sales projected near $1 billion and a robust pipeline expansion. Gross-to-net is expected to stabilize in the high 30s for 2026, with profitability anticipated after that. International growth will follow, and key clinical trials are on track for 2027 and 2028.
-
Rezdiffra achieved rapid commercial success and strong market access, with significant growth potential remaining in the underpenetrated MASH market. Pipeline expansion focuses on combination therapies, including GLP-1 and DGAT2 inhibitors, with key clinical readouts expected in 2027. Financial strategy prioritizes top-line growth and long-term profitability.
Fiscal Year 2025
-
Rezdiffra achieved nearly $1B in first-year net sales, establishing itself as the MASH standard of care amid a rapidly expanding US market. The company expects robust growth in 2026, driven by steady patient additions, pipeline expansion, and strong financials, despite higher gross to net impacts.
-
Strong sales momentum, robust payer access, and expanding prescriber engagement mark a successful launch phase. Clinical data supports chronic use and de-risks future studies, while strategic business development and patent protection position the company for long-term growth.
-
Strong launch momentum continues with over $1 billion run rate and less than 10% market penetration, supported by robust IP and payer access. Gross-to-net discounts will rise as contracting matures, with international expansion starting in Germany. Pipeline and label expansion remain top priorities.
-
Rezdiffra is positioned as a foundational therapy for MASH, with strong long-term growth potential and high persistency rates. Commercial strategy focuses on specialist engagement and patient support, while financial guidance anticipates a gross-to-net impact in the high 30% range for 2026. Clinical trials in advanced populations are progressing, with key results expected in 2027.
-
Rezdiffra delivered $287.3M in Q3 2025 net sales, up 35% sequentially, with over 29,500 patients on therapy and more than 10,000 prescribers. Robust U.S. demand, expanding payer access, and a strong pipeline—including a new oral GLP-1—support continued growth into 2026.
-
Significant progress was highlighted, including a strong Rezdiffra launch, robust IP protection through 2045, and European expansion. Real-world data supports high efficacy and adherence, while pipeline growth and $500M in financing position the company for long-term leadership in MASH.
-
Recent achievements include a new U.S. patent, strong U.S. launch metrics, and positive F4c clinical data. The company is preparing for a Germany launch, advancing a GLP-1 combination, and expects further growth with ongoing market and clinical expansion.
-
Q2 2025 net sales rose 55% to $212.8M, with Rezdiffra annualizing at $800M+ and strong prescriber adoption. New U.S. patent extends exclusivity to 2045, and international expansion is underway. Gross-to-net discounts are expected to remain within 20%-30% for 2025.
-
A top-tier specialty launch has achieved rapid adoption, strong payer coverage, and positive real-world feedback, with over 17,000 patients treated and robust prescriber engagement. Ongoing clinical trials, lifecycle management, and a strategic European rollout underpin long-term growth and IP extension.
-
Rezdiffra demonstrated sustained improvements in liver stiffness, portal hypertension risk, and multiple biomarkers over two years in patients with compensated MASH cirrhosis, with a favorable safety profile. These results support its potential as the first approved therapy for F4C, pending phase III outcomes in 2027.
-
Q1 2025 net sales rose 33% to $137.3M, with over 17,000 patients on Rezdiffra and strong prescriber growth. Expansion into F4c and Europe is on track, and robust cash reserves support ongoing launches. Management expects continued growth despite evolving competition.
-
Strong launch momentum with rapid patient uptake, broad prescriber engagement, and early payer access. Market penetration remains low, leaving significant growth runway, while future competition and pipeline expansion are expected to further drive awareness and leadership.
-
Rezdiffra's launch in MASH has exceeded expectations, achieving strong sales, rapid patient uptake, and foundational status in treatment guidelines. With robust financials and a clear strategy for geographic and pipeline expansion, leadership in this high unmet need market is expected to continue.
Fiscal Year 2024
-
Rezdiffra's launch drove $180M in 2024 net sales with rapid prescriber and patient uptake, strong payer coverage, and promising two-year cirrhosis data. Management expects robust growth in 2025, continued market expansion, and is preparing for European entry.
-
Strong launch momentum continues with robust revenue, patient growth, and prescriber engagement, supported by favorable payer dynamics and a differentiated product profile. International expansion is progressing with a disciplined, country-specific approach, and patent protection extends to 2038.
-
Strong Q3 performance with rapid patient and prescriber growth, early achievement of payer coverage, and efficient distribution. International expansion is on track for 2025, with disciplined market entry and supportive guidelines. Ongoing system integration and no immediate pricing pressure from GLP-1 competition.
-
Q3 saw strong revenue and patient growth, with rapid prescriber expansion and broad payer coverage. Combination use with GLP-1s is rising, and the company is well-positioned for both U.S. and European market growth, with robust IP and a focus on MASH leadership.
-
Q3 2024 saw $62M in net sales and over 6,800 patients on Rezdiffra, with >80% commercial coverage achieved ahead of schedule. Strong growth is expected to continue into Q4 and 2025, supported by robust demand, expanding prescriber base, and a solid cash position.
-
Strong initial launch with over 2,000 patients and $14.6M in Q2 sales, supported by expanding payer coverage and early physician adoption. Strategic focus includes global expansion, portfolio growth, and leadership in NASH/MASH, with minimal payer barriers and robust clinical guidance.
-
A first-in-class NASH therapy is off to a strong launch, with over 2,000 patients on therapy, $14.6M in Q2 sales, and rapid payer coverage expansion. The company is executing a disciplined, long-term growth strategy in both the US and Europe, with robust IP and a focus on sustained leadership.
-
Rezdiffra’s Q2 2024 launch generated $14.6M in net sales, with over 2,000 patients on therapy and more than 50% of commercial lives covered. The company is expanding in Europe, maintaining strong cash reserves, and expects continued growth as system integration and payer coverage progress.
-
Significant progress has been made in commercializing a new NASH therapy, with strong early launch execution, robust long-term data, and a clear first-mover advantage. Payer access is expanding, and future outcomes data could further increase market potential.